Thu Nov 26 2020

Mikkeli Central Hospital in Finland, serving an area with 100,000 residents and 200 beds, has become the first to routinely use suPARnostic® TurbiLatex clinically after a pilot study with about 1,700 patients. They aim to enhance triage efficiency in the emergency department with its immediate implementation. Key findings from their study show a 99.3% chance of survival for patients with suPAR levels below 4 ng/ml, and a 92.6% ability to identify those at low risk. Patients with levels above 6 ng/ml require immediate attention, indicated by an 11.6% chance of complications and a 77.4% accuracy in identifying those at high risk. suPAR levels, alongside factors like sex, age, and CRP levels, significantly influence risk assessments, doubling the 90-day mortality risk by 96%. To discover more about these findings, Mikkeli Hospital encourages viewing their full presentation.

Swedish provider of health tests will now be using our QuickTriage product

A Swedish health test provider has chosen to add suPARnostic® Quick Triage to its standard panel for corporate clients. This provider delivers a variety of health tests, focusing on physiological and biological parameters, to its clientele across Sweden. They will now incorporate suPARnostic® Quick Triage into their offerings.

Jakob Knudsen, Chief Executive Officer of ViroGates, says:”We’re thrilled to announce our first clinical routine customer in Finland, Mikkeli Central Hospital. Our collaboration showcased suPARnostic®’s value in central hospital triage. The pilot study’s convincing results have led the hospital to swiftly adopt our products, even before publishing the study’s outcomes. We’re eagerly awaiting these results and are preparing the first commercial shipment for use with the hospital’s Roche cobas system. Additionally, today we received our first order from the corporate health screening market in Sweden. This new market appreciates suPARnostic® for measuring employee inflammation levels in large organizations. We’re excited about this market’s potential, as more people aim to proactively manage and improve their health status.”

1000+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of four products:

Quick Triage
TurbiLatex
ELISA
POC+

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates